ACM
CRVS icon

ADAR1 Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

ADAR1 Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,000
Closed -$80.3K – 223
2024
Q4 		$80.3K Buy
+15,000
New +$112K 0.02% 187

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ADAR1 Capital Management's CRVS Position: Q1 2026 in Review

ADAR1 Capital Management reduced its Corvus Pharmaceuticals (CRVS) stake by 81% in Q1 2026, selling an estimated $6.03M and leaving 87,901 shares worth $1.29M. The position accounts for 0.08% of the portfolio, ranked #140.

ADAR1 Capital Management first reported a position in CRVS in Q4 2025 and has held it in 2 quarters since. The position peaked at $3.59M in Q4 2025. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • ADAR1 Capital Management held 87,901 shares of Corvus Pharmaceuticals worth $1.29M as of Q1 2026.
  • ADAR1 Capital Management sold 377,974 Corvus Pharmaceuticals shares in Q1 2026, an estimated $6.03M.
  • Corvus Pharmaceuticals made up 0.08% of ADAR1 Capital Management's portfolio in Q1 2026, its #140 holding.
  • ADAR1 Capital Management first reported a position in Corvus Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • ADAR1 Capital Management's Corvus Pharmaceuticals position peaked at $3.59M in Q4 2025.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.